The Japanese big pharma adds the new gene therapy candidate to its pipeline in a US$50 million deal in equity and upfront ...

The asset, AVB-101, is being evaluated in a phase 1/2 trial in frontotemporal dementia with progranulin mutations. The deal ...

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...

Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic ...

AviadoBio and Astellas Pharma announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene ...

UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license ...

Astellas will make a $20 million equity investment in AviadoBio for the option to exclusively develop and commercialize AVB-1010.

Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 ...

The agreement leverages King's College London spin-out company's expertise in developing targeted gene therapy for ...

“In contrast, intrathalamic delivery of AVB-101 in sheep and non-human primates was well tolerated and achieved human physiological levels of human progranulin (hPGRN) throughout the brain” (Fi ...